RE: SNG P3 Results Due...13 Feb 2022 12:44
Interferon-ß acts directly on T cells to prolong allograft survival by enhancing regulatory T cell i12 Feb 2022 20:12
Looks to be a newly published study, full details behind a paywall, but the summary seems pretty good if you've got a product that can deliver INFb to the human body without the side effects associated with subcutaneous administration...
" Highlights
•
IFNß synergizes with CTLA-4 Ig to prolong allograft survival by promoting Treg cells
•
IFNß directly acts on T cells to enhance Treg cell induction
•
IFNß activates STAT1 signaling to promote P300 expression and increase Foxp3 acetylation
Summary
Type I interferons (IFNs) are pleiotropic cytokines with potent antiviral properties that also promote protective T cell and humoral immunity. Paradoxically, type I IFNs, including the widely expressed IFNß, also have immunosuppressive properties, including promoting persistent viral infections and treating T-cell-driven, remitting-relapsing multiple sclerosis. Although associative evidence suggests that IFNß mediates these immunosuppressive effects by impacting regulatory T (Treg) cells, mechanistic links remain elusive. Here, we found that IFNß enhanced graft survival in a Treg-cell-dependent murine transplant model. Genetic conditional deletion models revealed that the extended allograft survival was Treg cell-mediated and required IFNß signaling on T cells. Using an in silico computational model and analysis of human immune cells, we found that IFNß directly promoted Treg cell induction via STAT1- and P300-dependent Foxp3 acetylation. These findings identify a mechanistic connection between the immunosuppressive effects of IFNß and Treg cells, with therapeutic implications for transplantation, autoimmunity, and malignancy."
https://www.cell.com/immunity/ppt/S1074-7613(22)00040-1.ppt
Credit to Brand on SNG Board..
Sign In
Follow the stocks
